A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

Christina A. Rostad; Robert L. Atmar; Emmanuel B. Walter; Sharon E. Frey; Jeffery L. Meier; Amy C Sherman; Lilin Lai; Rachel Tsong; Carol Kao; Vanessa Raabe; Hana M. El Sahly; Wendy A. Keitel; Jennifer A. Whitaker; Michael J. Smith; Kenneth E. Schmader; Geeta K. Swamy; Getahun Abate; Patricia L. Winokur; Wendy Buchanan; Kaitlyn Cross; Ashley Wegel; Yongxian Xu; İnci Yıldırım; Satoshi Kamidani; Nadine Rouphael; Paul C. Roberts; Mark J. Mulligan; Evan J. Anderson

doi:10.1093/cid/ciae173

Abstract

A surge of human influenza A(H7N9) cases began in 2016 in China from an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rostad et al. (2024) studied this question.

synapsesocial.com/papers/68e721fab6db64358769b87d https://doi.org/10.1093/cid/ciae173

View Full Paper

Ask AI

Bookmark

Share

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

Abstract

Discussion

Cite This Study

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

Abstract

Discussion

Cite This Study

Keep reading

Keep reading